12 November 2026

Australian Securities Exchange
39 Martin Place
Sydney NSW 2000

2026 Annual General Meeting

Chair Address and Presentation

Melbourne, Australia – Alcidion Group Limited (ASX: ALC) (**Alcidion** or **Company**) advises in accordance with ASX Listing Rule 3.13.3, a copy of the address by Chair, Rebecca Wilson and slides to be presented at today's Annual General Meeting are attached.

ENDS

Authorised for ASX release by the Board of Alcidion Group Limited.

For further information, please contact:

Investor Relations
investor@alcidion.com

About Alcidion

Alcidion Group Limited has a simple purpose, that is, to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations, worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver Clinical Decision Support at the point of care; all in support of Alcidion's mission to improve patient outcomes.

Since listing on the ASX in 2016, Alcidion has acquired multiple healthcare IT companies and expanded its foothold in the UK, Australia, and New Zealand to now service over 400 hospitals and 87 healthcare organisations, with further geographical expansion planned. With over 20 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

www.alcidion.com

© Alcidion Group Limited 2026

Chair's Address

Good afternoon, everyone, and thank you for joining us for Alcidion's 2026 Annual General Meeting.
FY26 was a standout year for Alcidion. It was the year we moved decisively from transformation to traction, and it has set the foundation for continued growth over the years ahead.

We delivered our strongest financial performance to date, with growth across every key measure. Kate will take you through the detail shortly, but from the Board's perspective, three things stand out.

First, the quality of our growth. More of our revenue now comes from recurring, multi-year partnerships with some of the most respected health systems in Australia, New Zealand and the United Kingdom. That gives us more resilient earnings and greater visibility of the years ahead.

Second, our profitability and cash generation. We built on the profitability we first achieved in FY25, turned our earnings into cash and finished the year with a strong balance sheet and debt free.

Third, our position in the market. Our flagship customers keep expanding with us adding new modules and deepening our partnership, plus we won our third Electronic Patient Record contract, and acquired Kyra Health to strengthen our leadership in patient flow here at home and substantially increase our customer footprint. The continued confidence of our customers is the strongest endorsement of our Miya platform. That momentum has carried into FY27, and we have reconfirmed our guidance that revenue and underlying EBITDA will exceed FY26.

Above all of this is our purpose: helping clinicians make the right decisions and moving patients safely and efficiently through care. When our technology gives clinicians back time or allows patients to be cared for closer to home, it frees up capacity in health systems without the cost of building new hospitals. That is where impact and value come together, and it is why demand for what we do continues to grow.

The most important shift this year is that Alcidion's operational and financial maturity now gives us options. Today we are a profitable, cash-generating business. That gives the Board real choices about how we continue to build a resilient company and create lasting value for shareholders.

Our capital allocation framework sets out those choices. We will keep investing in Miya, including the AI-enabled capability that will define the next generation of healthcare technology. We will pursue growth in our existing markets and in new ones. We will consider acquisitions where they strengthen our position and add to earnings. And we will return capital to shareholders where that is the best use of funds.

These priorities complement one another, and we will manage them in a careful and measured way, always weighing which offers the best long-term return.

The on-market share buy-back is one example. It reflects the Board's confidence in Alcidion's outlook and gives us a lever within our control, which we will use selectively under the right conditions. The proposed share consolidation before you today is part of the same program, aligning our capital structure with the company we have become, and we thank you for your support.

Despite this very positive momentum and progress, we recognise shareholders' frustration that the share price is not yet aligning, in what have been challenging conditions for listed healthcare and smaller companies. Our focus is on what we can control: delivering results, deploying capital with discipline and engaging more actively with investors, so the market sees Alcidion for the business it has become.

As the business matures, so will the way we govern it, and that includes remuneration. Our incentives have served us well in building scale and profitability. Our commitment is that our remuneration framework, and the processes behind it, will continue to mature alongside the business. We appreciate the constructive input shareholders have shared with us. It will inform an independent review this year that we've commissioned to reflect the mature business we now are, and we will provide further disclosure in our next Remuneration Report.

Ownership is part of this too. Directors have long been expected to hold shares equal to at least one year's fees within three years of appointment, and we are now making this formal policy. Every director is a shareholder, and we share your interest in Alcidion's success.

On behalf of the Board, I thank our CEO, Kate Quirke, the senior leadership team and all our people for an outstanding year. I also thank our customers for their trust and you, our shareholders, for your continued support.

Alcidion enters FY27 with record contracted revenue, a growing base of recurring income, a debt-free balance sheet and a platform built for the AI era. We have a clear strategy, the financial strength to pursue it and the flexibility to choose the best path to build value. We are building a business where lasting financial value and meaningful healthcare impact go hand in hand, and the Board is confident in the road ahead.




ALCIDION

Annual General Meeting

12 November 2026

INTRODUCTION





ACKNOWLEDGEMENT OF COUNTRY

Alcidion acknowledges the Traditional Custodians of the land we live and work upon and pay our respects to Elders past and present.

COMMERICAL IN CONFIDENCE

Alcidion Group Board



Rebecca Wilson

Non-executive Chair

Experienced company director with private, ASX-listed and not-for-profit organisations. Rebecca has held global leadership roles in marketing communication, investor relations, and corporate affairs. She has deep expertise in ESG, complex stakeholder communication, issues, crisis and risk management, transactions, and investor relations.

Rebecca is currently the Chair of Clever Culture Systems Limited (ASX: CC5), NED of Hansen Technologies Limited (ASX: HSN) and Vitura Health Limited (ASX: VIT).



Kate Quirke

Group Managing Director/ Chief Executive Officer

25+ years of digital health sector experience. Kate has held leading management roles at large healthcare software firms, which has included large procurements and implementations of healthcare information technology across Australia, New Zealand, the United Kingdom and South-East Asia.



Daniel Sharp

Non-executive Director

25 years+ senior executive experience in investment banking and corporate finance. Daniel was previously Executive Director of Corporate Finance at Canaccord Genuity where he led dozens of IPOs, equity capital market transactions and corporate finance advisory projects across the healthcare, life sciences, technologies, financial services and general industrials sectors.

Daniel is currently a NED of Botanix Pharmaceuticals Limited (ASX: BOT).



Andrew Way

Non-executive Director

35+ years experience in senior healthcare leadership roles across both Australian and UK markets.

Andrew has been a Chief Executive for nearly 25 years, most recently as the CEO of Alfred Health in Melbourne, Victoria, finishing in 2024. Andrew has led several hospitals through major clinical and non-clinical digital transformations. Awarded an AM for his services in support of clinical research and leadership.

Andrew is currently Board Chair of HealthShare Victoria and a Director of Australian College of Health Service Management (ACHSM).



William Smart

Non-executive Director

Global digital health leader with 30+ years of experience leading transformational change in complex organisations. Based in the UK, Will is currently Digital NED, Great Western Hospitals NHS Foundation. He has held executive roles in several NHS Trusts including as Group Chief Information Officer, Royal Free London NHS Foundation Trust.

Until recently, Will served as the Global Director of External Relations, Dedalus Group where he had responsibilities across the UK and Europe and led the launch of its European built Electronic Patient Record (EPR) solution into Ireland and the UK.

Format of Meeting

01
Chair Address

02
Annual General Meeting Presentation

03
Q&A / Voting Procedure Overview

04
Formal Business of the Meeting

05
General Questions



01.

Chair Address



02.

Annual General Meeting Presentation



ALCIDION

FY26 AGM
CEO Presentation

12 November 2026

FY26 Snapshot

A Record FY26 for Alcidion...

ALCIDION

1

Growth

Revenue up 27%[1]

2

Profitability

Underlying EBITDA up 34%

Operating cashflow up 19%

NPAT positive

3

Referenceability

Multiple Flagship customer expansions + new EPR win

4

Market Need

Healthcare systems under increasing pressure to improve efficiency & bed availability

FY27 Momentum

Underpinned by increasing ARR & contracted future revenue

Capital management to drive shareholder returns

1. Compared to FY25 (prior corresponding period)

FY26 – Financial Highlights

Growth across all key financial metrics

ALCIDION

Revenue

$51.6M

Up 27% on pcp[1]

Driven by several contract wins and expansions

ARR[2] (as at 30 Jun-26)

$38.3M

Up 34% on pcp

Incl. ARR of $3.6M from Kyra products acquisition

Increasing recurring revenue base underpinned by long-term contracts

New & renewal TCV

$78.5M

Up 6% on pcp

$62.2m (or 79%) represents new contract sales

EBITDA[3]

$6.2M

Up 28% on pcp

Underlying EBITDA of $6.8M (up 34% on pcp)

Positive operating cashflow

$6.8M

Up 19% on pcp

$20.6M cash, **no debt** as at 30 June 2026

1. Comparisons are to prior corresponding period (FY25)
2. Annual Recurring Revenue defined as the value of Support & Maintenance (S&M), hosting and/or license revenue expected to be billed over the next 12 months. This does not include multi-year capital licenses paid during the year which will reoccur again upon a future contract renewal. ARR is a measure of the future annualised revenue as at a point in time.
3. EBITDA: includes share-based payments ($199k) and one-off restructure costs ($236k) and M&A transaction costs ($175k).

FY26 – Operational Highlights

Continuing sales momentum + strategic patient flow acquisition

New + expanded contracts

NHS North Cumbria Integrated Care NHS Foundation Trust	Mizaic partnership + non- clinical comms
leidos / Australian Government Department of Defence	Additional Miya capability + sites
Gold Coast Health always care	Virtual care
NHS University Hospitals Sussex NHS Foundation Trust	EPR

Post FY26 period end:

NHS Northern Care Alliance NHS Foundation Trust	Upgrade to Miya patient flow

Extensions / Renewals

NHS Bolton NHS Foundation Trust	Patientrack
NHS Lanarkshire	Patientrack
NHS Northumbria Healthcare NHS Foundation Trust / NHS Harrogate and District NHS Foundation Trust	PCS PAS renewal
Western Health	Patient flow


Kyra Flow Products Acq.

- Completed acquisition on 29 June 2026
- Added 33 new customers (31 new) – both private and public
- Consolidated leadership position in Australian patient flow market; particularly in Qld
- Immediately earnings accretive

Growing Customer Footprint


100+ healthcare clients across the UK, Australia and NZ - from NHS trusts to defence health

United Kingdom 40+ NHS trusts[1]



1. **NHS Fife**
   Patientrack observations and Smartpage
2. **NHS Lanarkshire**
   Patientrack (renewed FY26)
3. **North Cumbria Integrated Care**
   Miya Precision EPR (~10 yrs), plus clinical comms
4. **South Tees Hospitals**
   Multi-module Miya Precision, now incl. Miya ED
5. **Bolton & East Lancashire**
   Miya Flow upgrades from ExtraMed; observations
6. **Hywel Dda (Wales)**
   Miya Flow and Miya ED
7. **Southampton & Hampshire**
   Miya Emergency across neighbouring trusts
8. **University Hospitals Sussex**
   Miya Precision EPR incl. Virtual Care (7 yrs)

Australia & New Zealand Every Australian state and territory[1]



Kyra flow products

33

long-standing customers added from Telstra Health in 2026; only two were existing relationships


1. **NT Health**
   Miya Precision patient flow
2. **Queensland**
   Gold Coast Health RPM; Kyra at most HHSs
3. **Sydney LHD (NSW)**
   Miya Virtual Care / RPM for 5+ years
4. **Leidos / Defence (ACT)**
   Defence health record and critical care
5. **Victoria**
   Alfred, Peninsula, Hume and Western Health
6. **NALHN (SA)**
   Miya Flow integrated with statewide EMR
7. **Western Australia**
   Kyra flow customers (public and private)
8. **Tasmania**
   Kyra flow customers
9. **New Zealand**
   All four regions, incl. Smartpage deployments

Expansion opportunities beyond core markets: Canada (growth market) · Middle East (delivery partnership) · Southeast Asia

Miya Patient Administration

Introducing Miya Patient Administration

The MIYA Platform



MIYA PATIENT ADMINISTRATION

Patient Entry
- ✓ Patient Registration
- ✓ Emergency Registration
- ✓ External Referrals
- ✓ Waiting List
- ✓ Encounter/Episode Management
- ✓ Internal Referrals

Admitted Care
- ✓ Inpatient Management
- ✓ Admission/Discharge/Transfer
- ✓ Ward Management
- ✓ Ward Attenders
- ✓ Patient Engagement
- ✓ Command Centre
- ✓ Clinical Coding/Grouping

Ambulatory & Scheduled Care
- ✓ Clinic Management
- ✓ Appointment Management
- ✓ Theatre Management

Frameworks & Reporting
- ✓ Audit/Security/Compliance
- ✓ Regulatory Reporting
- ✓ Operational Reporting

Built from the ground up, not anchored in the past

ALCIDION

30

YEARS

of patient administration experience carried forward

THE DEPTH OF PCS PAS

Using AI to deeply analyse the requirements from our PCS PAS blueprint.

BUILT NEW ON MIYA

Built from the ground up on Miya's modern platform.

SHAPED WITH CUSTOMERS

Ongoing engagement with our customers, carrying forward what we've learned without being anchored in the past.

We are taking advantage of the latest technology to transform patient administration

ALCIDION

01 SEAMLESS

Streamlined management of the patient's care

- Patients give their information once, not to every person they meet
- Pre-defined, automated workflows so each step builds on the last
- Every record is owned by the right person for that stage, so nothing is lost

02 INTEGRATED

Natively, with one record for every perspective

- More than administration: designed to support efficient clinical flow
- The platform approach meets reporting requirements without fragmenting records
- One data structure so nobody has to join up information manually

03 INTUITIVE

Like the best colleague you've ever worked with

- The details a task needs are brought forward as it begins
- The next step is suggested as soon as, or before, the last one is done
- Validation is part of the process
- New team members learn by use


04 INTELLIGENT

Always looking ahead

- A real-time view of what is happening now
- What is planned for tomorrow, next week and next month
- Machine learning and AI to predict demand and apply 'what if' analysis

Miya as the System of Record


Deepening our capability as the core system of record for healthcare organisations



- AI enablement
- Results Management
- Task Management
- Longitudinal Patient Record
- Patient Flow Management
- Virtual Care
- Predictive Analytics


- Clinical Record/CDR
- **Patient Administration**
- Master Patient Index
- Specialty Specific Systems

Scenario 1



Existing Health IT Solutions


Scenario 2



Growth Strategy & Outlook

Evolving our AI capability in Healthcare

Embracing the use of AI workflows whilst understanding and protecting client data/security



The Alcidion AI Framework

01 Knowledge Retrieval
(Conversational AI)

02 Documentation & Summarisation
(Generative AI)

03 Risk and Prediction
(Predictive AI)

04 Cohorts and Patterns
(Analytic AI)

05 Insight into Action
(Agentic AI)

© ALCIDION 2026

Growth Drivers

Multiple growth drivers underpinned by increasing customer referenceability

Alcidion Today

- 100+ healthcare customers
- 3 core geographies
- Profitable, debt-free and cash generative

1 Expand the installed base

- Cross-sell Miya modules
- Growth within existing hospital networks
- Miya and Kyra customer opportunities

2 Win new logos and geographies

- NHS digitisation & EPR replacement opportunities
- Grow patient flow and virtual care deployments
- First customer wins in selected international markets

3 Deepen platform capabilities

- Extend AI functionality
- Grow Miya as the patient engagement layer
- New workflows and care settings beyond hospitals

4 Disciplined platform expansion

- M&A opportunities for complementary products and capabilities
- Expand into adjacent care settings and geographies

Alcidion in the Future

- Leading recurring-revenue healthcare technology platform
- Larger and more deeply embedded installed base
- Broader AI-enabled product suite
- Greater exposure to virtual care & longitudinal health records
- Expanded geographic footprint

Capital Management & Outlook

Growing contracted revenue underpins confidence in future profitability and capital returns

Capital Management

- Driven by improving profitability and cash generation, the Board has greater flexibility to implement capital management frameworks that drive shareholder value.
- The frameworks balances:
  - Investment in the Miya platform (ie Patient Administration);
  - Expansion into new markets;
  - Potential strategic acquisitions; and
  - Capital returns.
- Recently announced **on-market share buy-back** and **share consolidation** form part of this framework:
  - On-market share buy-back of up to 10% of the issued capital (~135 million ordinary shares). Buy-back to be used selectively and ensuring sufficient capital for other growth initiatives
  - Share consolidation – proposed 10 shares into 1 share

Outlook

- As of 30 September 2026, contracted & renewal revenue expected to be recognised in FY27 of $50.0M, up 38% on pcp
- Confident of new customers and module expansions from land-and-expand strategy & growing customer referenceability
- Demand for modern electronic patient records, patient flow and virtual care solutions continues to grow as health systems prioritise reducing wait times and making the best use of bed capacity

Reconfirmed FY27 Guidance

- FY27 Revenue and Underlying EBITDA to exceed FY26



03.

Q&A / Voting Procedure Overview



04.

Formal Business of the Meeting

Financial Statements and Reports

To receive and consider the Company's Financial Statements, Directors' Report and Auditor's Report for the financial year ended 30 June 2026.

Further Information

- Matthew Gepp, Chief Financial Officer of Alcidion Group Limited and Grant Martinella of William Buck, the Company's external Auditor are present and available to answer any queries.
- Please note there is no vote required for this Item.

Resolution 1 – Adoption of Remuneration Report

To consider and, if thought fit, pass the following as an ordinary resolution:

"That for the purpose of section 250R(2) of the Corporations Act and for all other purposes, approval is given for the adoption of the Remuneration Report as contained in the Company's Annual Report for the year ended 30 June 2026."

FOR	AGAINST	PROXY'S DISCRETION	ABSTAIN
366,472,458	17,113,232	208,499	174,073,501
95.49%	4.46%	0.05%	-

Further Information

- Voting restrictions apply to Key Management Personnel and their closely related parties.
- The vote on this Resolution is advisory only and does not bind the Directors or Company.
- The Board recommends that Shareholders vote in FAVOUR of this Resolution.
- The Chair of the Meeting intends to vote undirected proxies in FAVOUR of this Resolution.

Resolution 2 – Re-election of Rebecca Wilson as a Director

To consider and, if thought fit, pass the following as an ordinary resolution:

"That, Rebecca Wilson, being a Director who retires by rotation pursuant to Clause 21.1 of the Constitution and Listing Rule 14.4 and who, being eligible, offers herself for re-election, be re-elected as a Director of the Company."

FOR	AGAINST	PROXY'S DISCRETION	ABSTAIN
587,779,407	15,429,214	208,499	1,517,493
97.41%	2.56%	0.03%	-

Further Information

- The Board (with Rebecca Wilson abstaining) recommends that Shareholders vote in FAVOUR of this Resolution.
- The Chair of the Meeting intends to vote undirected proxies in FAVOUR of this Resolution.

Resolution 3 – Consolidation of Capital

ALCIDION

To consider and, if thought fit, pass the following as an ordinary resolution:

"That, pursuant to section 254H of the Corporations Act, Listing Rules 7.20 and 7.21 and for all other purposes, approval is given for the issued capital of the Company to be consolidated on the basis that:

(a) every ten (10) Shares be consolidated into one (1) Share; and

(b) every ten (10) Performance Rights be consolidated into one (1) Performance Right,

and where the consolidation results in a fraction of a Security being held, the Company be authorised to round that fraction up to the nearest whole Security."

FOR	AGAINST	PROXY'S DISCRETION	ABSTAIN
551,330,401	52,004,924	260,499	1,338,789
91.34%	8.62%	0.04%	-

Further Information

- The Board recommends that Shareholders vote in FAVOUR of this Resolution.
- The Chair of the Meeting intends to vote undirected proxies in FAVOUR of this Resolution.



VOTING CLOSURE AND END OF FORMAL BUSINESS



05.

General Questions

THANK YOU

FOR YOUR ATTENDANCE


ALCIDION